Compare MINISO Group Holding Ltd (MNSO) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MINISO Group Holding Ltd vs State Street SPDR S&P Biotech ETF — how do they compare? MINISO Group Holding Ltd trades at $12.11 (market cap $3.62B), while State Street SPDR S&P Biotech ETF trades at $159.12. The key difference: MINISO Group Holding Ltd pays a 5.53% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, MINISO Group Holding Ltd nearer its low. Which is the better fit depends on your goals.
| MNSO | XBI | |
|---|---|---|
Market Cap | $3.62B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $26.63 | $164.28 |
52-Week Low | $11.30 | $88.79 |
Enterprise Value | $4.29B | — |
Dividend Yield | 5.53% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MNSO trades at $11.9, down 4.95% in the last session, with technical indicators showing a neutral to bearish bias. Recent earnings show volatility, with a Q1 2026 beat but prior misses, while fundamentals reveal solid revenue growth and improving profitability. The company announced a HK$2 billion share repurchase program in June 2026, signaling confidence.
The outlook is mixed: strong analyst buy ratings (75%) and undervalued metrics like a P/E of 12.16 support upside, but recent price declines and competitive pressures pose risks. Earnings consistency and margin sustainability are key for investor confidence.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About MINISO Group Holding Ltd
MINISO Group Holding Ltd is a global lifestyle product retailer known for its aesthetically pleasing, high-quality, and low-cost goods. The company operates a network of branded stores worldwide, offering a diverse range of merchandise, including household goods, cosmetics, toys, and digital accessories. MINISO's business model emphasizes rapid product iteration, efficient supply chain management, and a joint venture and franchise partner network to facilitate its global expansion.
Read more on MNSO →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
